Roth Capital Partners


Roth Capital Reiterates Hold on China Cord Blood Corporation (CO) Following “Noisy” Earnings

On August 19, China Cord Blood Corporation (NYSE:CO), China’s top umbilical cord blood storage services provider, released its preliminary unaudited financial results for …

Roth Capital Reiterates Buy On Cytori After Receving Funding From BARDA

Cytori Therapeutics (NASDAQ:CYTX) announced that BARDA executed the option to fund the continued development of Cytori Cell Therapy for thermal burn injuries. The current …

Roth Capital Reduces Black Diamond Price Target To $10 Following 2Q14 Earnings Results

In a report issued yesterday, Roth Capital analyst Dave King affirmed coverage on Black Diamond (BDE) with a Buy rating and reduced his price target to $10 (from $11). …

Roth Capital Maintains Buy on Hudson Ahead Of 2Q14 Earnings

Roth Capital’s analyst Philip Shen today maintained a Buy rating on Hudson Technologies Inc. (HDSN) and sets the target price at $6.

Roth Capital Reiterates Buy On Ligand Pharmaceutical Following Partnership With TG

In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharmaceutical (LGND) and a price target of $92.00 following …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts